TY  - JOUR
AU  - Džoljić, Eleonora
AU  - Sarić-Matutinović, Marija
AU  - Stojković, Oliver
AU  - Veličković, Jelena
AU  - Milinković, Neda
AU  - Kostić, Vladimir
AU  - Ignjatović, Svetlana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5179
AB  - Background: Vitamin D is a steroid hormone, known to be involved in the pathogenesis of various neurodegenerative disorders, including Parkinson's disease (PD). We aimed to clarify the relationship between hypovitaminosis D and the predisposition for PD and its clinical presentation. An additional aim was to examine the specific gene polymorphisms associated with vitamin D level. Material and methods: Total level of 25(OH)-vitamin D (25(OH)D) was measured in the serum of parkinsonian patients (n = 113) and controls (n = 82) using a commercial immunoassay. Genetic analyses were performed using Taqman assays on Real Time PCR amplification system. Results: Higher frequency of vitamin D deficiency (<50 nmol/L) was observed in PD patients, compared to controls (40.7% and 23.2%, respectively, P = 0.010). It was also a positive predictive marker of PD (OR, 2.27; 95% CI, 1.206–4.298; P < 0.011). Significantly higher UPDRS (35.85 ± 1.35 and 32.09 ± 0.99, respectively, P = 0.023) and HY scores (2(1.5–2.5) and 1.5(1.0–2.0), respectively, P = 0.005) were present in patients with 25(OH)D level < 50 nmol/L compared to patients with 25(OH)D level ≥ 50 nmol/L. Despite some trends observed, differences in allelic and genotypic distribution between controls and patients, as well as between subgroups, did not reach the level of significance (P > 0.05). Conclusions: Findings of this study confirm the hypothesis of a significant relationship between hypovitaminosis D and PD. We demonstrated higher prevalence of vitamin D deficiency in PD patients, as well as its predictive potential for the onset and progression of PD.
PB  - Elsevier Ltd
T2  - Neuroscience
T1  - Vitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease
VL  - 533
SP  - 53
EP  - 62
DO  - 10.1016/j.neuroscience.2023.10.004
ER  - 

@article{
author = "Džoljić, Eleonora and Sarić-Matutinović, Marija and Stojković, Oliver and Veličković, Jelena and Milinković, Neda and Kostić, Vladimir and Ignjatović, Svetlana",
year = "2023",
abstract = "Background: Vitamin D is a steroid hormone, known to be involved in the pathogenesis of various neurodegenerative disorders, including Parkinson's disease (PD). We aimed to clarify the relationship between hypovitaminosis D and the predisposition for PD and its clinical presentation. An additional aim was to examine the specific gene polymorphisms associated with vitamin D level. Material and methods: Total level of 25(OH)-vitamin D (25(OH)D) was measured in the serum of parkinsonian patients (n = 113) and controls (n = 82) using a commercial immunoassay. Genetic analyses were performed using Taqman assays on Real Time PCR amplification system. Results: Higher frequency of vitamin D deficiency (<50 nmol/L) was observed in PD patients, compared to controls (40.7% and 23.2%, respectively, P = 0.010). It was also a positive predictive marker of PD (OR, 2.27; 95% CI, 1.206–4.298; P < 0.011). Significantly higher UPDRS (35.85 ± 1.35 and 32.09 ± 0.99, respectively, P = 0.023) and HY scores (2(1.5–2.5) and 1.5(1.0–2.0), respectively, P = 0.005) were present in patients with 25(OH)D level < 50 nmol/L compared to patients with 25(OH)D level ≥ 50 nmol/L. Despite some trends observed, differences in allelic and genotypic distribution between controls and patients, as well as between subgroups, did not reach the level of significance (P > 0.05). Conclusions: Findings of this study confirm the hypothesis of a significant relationship between hypovitaminosis D and PD. We demonstrated higher prevalence of vitamin D deficiency in PD patients, as well as its predictive potential for the onset and progression of PD.",
publisher = "Elsevier Ltd",
journal = "Neuroscience",
title = "Vitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease",
volume = "533",
pages = "53-62",
doi = "10.1016/j.neuroscience.2023.10.004"
}

Džoljić, E., Sarić-Matutinović, M., Stojković, O., Veličković, J., Milinković, N., Kostić, V.,& Ignjatović, S.. (2023). Vitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease. in Neuroscience
Elsevier Ltd., 533, 53-62.
https://doi.org/10.1016/j.neuroscience.2023.10.004

Džoljić E, Sarić-Matutinović M, Stojković O, Veličković J, Milinković N, Kostić V, Ignjatović S. Vitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease. in Neuroscience. 2023;533:53-62.
doi:10.1016/j.neuroscience.2023.10.004 .

Džoljić, Eleonora, Sarić-Matutinović, Marija, Stojković, Oliver, Veličković, Jelena, Milinković, Neda, Kostić, Vladimir, Ignjatović, Svetlana, "Vitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease" in Neuroscience, 533 (2023):53-62,
https://doi.org/10.1016/j.neuroscience.2023.10.004 . .

TY  - JOUR
AU  - Radojević, Branislava
AU  - Dragašević-Mišković, Nataša
AU  - Marjanović, Ana
AU  - Branković, Marija
AU  - Milovanović, Andona
AU  - Petrović, Igor
AU  - Svetel, Marina
AU  - Jančić, Ivan
AU  - Stanisavljević, Dejana
AU  - Milićević, Ognjen
AU  - Savić, Miroslav
AU  - Kostić, Vladimir
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4082
AB  - Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.
PB  - Elsevier Ltd
T2  - Parkinsonism and Related Disorders
T1  - The correlation between genetic factors and freezing of gait in patients with Parkinson's disease
VL  - 98
SP  - 7
EP  - 12
DO  - 10.1016/j.parkreldis.2022.03.018
ER  - 

@article{
author = "Radojević, Branislava and Dragašević-Mišković, Nataša and Marjanović, Ana and Branković, Marija and Milovanović, Andona and Petrović, Igor and Svetel, Marina and Jančić, Ivan and Stanisavljević, Dejana and Milićević, Ognjen and Savić, Miroslav and Kostić, Vladimir",
year = "2022",
abstract = "Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.",
publisher = "Elsevier Ltd",
journal = "Parkinsonism and Related Disorders",
title = "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease",
volume = "98",
pages = "7-12",
doi = "10.1016/j.parkreldis.2022.03.018"
}

Radojević, B., Dragašević-Mišković, N., Marjanović, A., Branković, M., Milovanović, A., Petrović, I., Svetel, M., Jančić, I., Stanisavljević, D., Milićević, O., Savić, M.,& Kostić, V.. (2022). The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders
Elsevier Ltd., 98, 7-12.
https://doi.org/10.1016/j.parkreldis.2022.03.018

Radojević B, Dragašević-Mišković N, Marjanović A, Branković M, Milovanović A, Petrović I, Svetel M, Jančić I, Stanisavljević D, Milićević O, Savić M, Kostić V. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders. 2022;98:7-12.
doi:10.1016/j.parkreldis.2022.03.018 .

Radojević, Branislava, Dragašević-Mišković, Nataša, Marjanović, Ana, Branković, Marija, Milovanović, Andona, Petrović, Igor, Svetel, Marina, Jančić, Ivan, Stanisavljević, Dejana, Milićević, Ognjen, Savić, Miroslav, Kostić, Vladimir, "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease" in Parkinsonism and Related Disorders, 98 (2022):7-12,
https://doi.org/10.1016/j.parkreldis.2022.03.018 . .

TY  - JOUR
AU  - Kostić, Vladimir
AU  - Džoljić, Eleonora
AU  - Todorović, Zoran
AU  - Mijajlović, Milija
AU  - Svetel, Marina
AU  - Stefanova, Elka
AU  - Dragašević, Nataša
AU  - Petrović, Igor
AU  - Milošević, Milenko
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1825
AB  - Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.
AB  - Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine
T1  - Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
VL  - 69
IS  - 12
SP  - 1067
EP  - 1075
DO  - 10.2298/VSP111114028K
ER  - 

@article{
author = "Kostić, Vladimir and Džoljić, Eleonora and Todorović, Zoran and Mijajlović, Milija and Svetel, Marina and Stefanova, Elka and Dragašević, Nataša and Petrović, Igor and Milošević, Milenko and Kovačević, Ivan and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted., Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine, Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi",
volume = "69",
number = "12",
pages = "1067-1075",
doi = "10.2298/VSP111114028K"
}

Kostić, V., Džoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragašević, N., Petrović, I., Milošević, M., Kovačević, I., Miljković, B., Pokrajac, M.,& Prostran, M.. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 69(12), 1067-1075.
https://doi.org/10.2298/VSP111114028K

Kostić V, Džoljić E, Todorović Z, Mijajlović M, Svetel M, Stefanova E, Dragašević N, Petrović I, Milošević M, Kovačević I, Miljković B, Pokrajac M, Prostran M. Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled. 2012;69(12):1067-1075.
doi:10.2298/VSP111114028K .

Kostić, Vladimir, Džoljić, Eleonora, Todorović, Zoran, Mijajlović, Milija, Svetel, Marina, Stefanova, Elka, Dragašević, Nataša, Petrović, Igor, Milošević, Milenko, Kovačević, Ivan, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine" in Vojnosanitetski pregled, 69, no. 12 (2012):1067-1075,
https://doi.org/10.2298/VSP111114028K . .

TY  - JOUR
AU  - Todorović, Zoran
AU  - Džoljić, Eleonora
AU  - Novaković, Ivana
AU  - Mirković, Duško
AU  - Stojanović, Radan
AU  - Nesić, Zorica
AU  - Krajinović, Maja
AU  - Prostran, Milica
AU  - Kostić, Vladimir
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/666
AB  - Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.
PB  - Elsevier Science BV, Amsterdam
T2  - Journal of the Neurological Sciences
T1  - Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy
VL  - 248
IS  - 1-2
SP  - 56
EP  - 61
DO  - 10.1016/j.jns.2006.05.040
ER  - 

@article{
author = "Todorović, Zoran and Džoljić, Eleonora and Novaković, Ivana and Mirković, Duško and Stojanović, Radan and Nesić, Zorica and Krajinović, Maja and Prostran, Milica and Kostić, Vladimir",
year = "2006",
abstract = "Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Journal of the Neurological Sciences",
title = "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy",
volume = "248",
number = "1-2",
pages = "56-61",
doi = "10.1016/j.jns.2006.05.040"
}

Todorović, Z., Džoljić, E., Novaković, I., Mirković, D., Stojanović, R., Nesić, Z., Krajinović, M., Prostran, M.,& Kostić, V.. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences
Elsevier Science BV, Amsterdam., 248(1-2), 56-61.
https://doi.org/10.1016/j.jns.2006.05.040

Todorović Z, Džoljić E, Novaković I, Mirković D, Stojanović R, Nesić Z, Krajinović M, Prostran M, Kostić V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences. 2006;248(1-2):56-61.
doi:10.1016/j.jns.2006.05.040 .

Todorović, Zoran, Džoljić, Eleonora, Novaković, Ivana, Mirković, Duško, Stojanović, Radan, Nesić, Zorica, Krajinović, Maja, Prostran, Milica, Kostić, Vladimir, "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy" in Journal of the Neurological Sciences, 248, no. 1-2 (2006):56-61,
https://doi.org/10.1016/j.jns.2006.05.040 . .